Navigation Links
Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program
Date:10/12/2010

SCOTTSDALE, AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures Corporation (OTC:BB: DYNV), is pleased to announce that the Editorial Board of Standard and Poor's ("S&P") has approved Dynamic Ventures Corporation for their Corporation Records Market Access Program. Standard & Poor's Corporation Records is considered the premier source for information on U.S. and international public companies by investors and compliance professionals. As part of the approval, DYNV's corporate profile has recently been published in the Daily News Section of S&P's Corporation Records, a recognized securities manual for secondary trading in 38 States under the Blue Sky Laws.

Paul Kalkbrenner, President/CEO of Dynamic Ventures "Now that Dynamic has met the state-level "Blue Sky" statutes, its securities can be recommended to investors in those jurisdictions. Through Standard and Poor's program, Dynamic's company information, including its business operations, share price, dividend history, shares outstanding, financial position, and earnings, will be broadly disseminated through S&P's MarketScope, Advisor Insight and Stock Guide Database distribution channels."

About The Company:

Dynamic Ventures Corporation, soon to be renamed Bundled Builder Solutions, Inc., develops and markets efficient construction solutions for residential and commercial buildings. Its EZ-Build subsidiary offers a turnkey solution enabling the firm to custom design, manufacture and install complete LEED certified structures. The overall energy efficient, affordable, green, easy and quick construction approach offered by the EZ-Build system is unique in the industry.

This press release contains forward-looking statements that involve risks and uncertainties, including the Company's beliefs about its business prospects and future results of operations. Some factors that could cause actual results to differ materially include economic and operational risks, changes in anticipated earnings, continuation of current contracts, and other factors detailed in the Company's filings with the Securities and Exchange Commission, including its most recent Forms 10-KSB and 10-QSB. The Company forecasts provided above are dynamic and therefore refer only to this release date. The Company does not undertake to update any forecasts that it may make available to the investing public.


'/>"/>
SOURCE Dynamic Ventures Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CardioDynamics Reports Third Quarter 2008 Results, Seventh Consecutive Quarterly Revenue Growth and 15% Year to Date Revenue Increase
2. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
3. Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products
4. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
5. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
6. Visual i/o Combines Advanced Dynamic Visual Business Intelligence and Search Through New Software
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
9. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
10. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
11. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):